Solid Tumors clinical trials in New Jersey
147 active Solid Tumors trials with a site in New Jersey. Describe your situation to see which ones look like a fit.
- SLV-154 Treatment of Advanced Cancers
- A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
- Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
- Study of GS-2426 in Participants With Advanced Solid Tumors
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
- A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
- Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
- TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
- A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
- A Study of BG-C477 in Participants With Advanced Solid Tumors
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
- A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
- A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
- First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
- A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
- First in Human, Dose Escalation Study of AN4005
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
- A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- A Study of ASP3082 in Adults With Advanced Solid Tumors
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
- Visugromab in Cachexia International Trial
- A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.